ANALYSIS OF DASATINIB AND IMATINIB 5-YEAR EFFICACY AND SAFETY BASED ON BASELINE COMORBIDITY AND AGE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) IN DASISION

被引：0
|
作者：
Saglio, G. [1 ]
Cortes, J. E. [2 ]
Hochhaus, A. [3 ]
Shah, N. P. [4 ]
Atallah, E. L. [5 ,6 ]
Abaskharoun, M. [7 ]
Li, L. [7 ]
Mauro, M. J. [8 ]
机构：
[1] Univ Turin, Turin, Italy
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Klinikum Jena, Jena, Germany
[4] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
[5] Froedtert, Milwaukee, WI USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Bristol Myers Squibb Co, Princeton, NJ USA
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1060
引用
收藏
页码：436 / 437
页数：2
相关论文
共 50 条
  • [41] Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd.
    Larson, Richard A.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Rosti, Gianantonio
    Lopez, Jose L.
    Stenke, Leif
    Nakamae, Hirohisa
    Goldberg, Stuart L.
    Wang, Ming-Chung
    Gallagher, Neil J.
    Hoenekopp, Albert
    Ortmann, Christine-Elke
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 944 - 945
  • [42] Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety
    Khoury, H. J.
    Goldberg, S. L.
    Mauro, M. J.
    Stone, R. M.
    Matloub, Y.
    Chen, T.
    Guilhot, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] DASATINIB LACK OF CROSS INTOLERANCE TO IMATINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (CML-CP) WHO ARE INTOLERANT TO IMATINIB - A RETROSPECTIVE SAFETY ANALYSIS
    Guilhot, E.
    Goldberg, S. L.
    Stone, R. M.
    Mauro, M.
    Matloub, Y.
    Chen, T. T.
    Khoury, H. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 51 - 51
  • [44] THE IMPACT OF EARLY MOLECULAR RESPONSE ON LONG-TERM OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH DASATINIB OR IMATINIB FROM THE DASISION TRIAL
    Stegelmann, F.
    Shah, N. P.
    Saglio, G.
    Hochhaus, A.
    Bilmes, R.
    Li, L.
    Cortes, J. E.
    HAEMATOLOGICA, 2016, 101 : 240 - 240
  • [45] Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia
    周励
    ChinaMedicalAbstracts(InternalMedicine), 2013, 30 (02) : 123 - 123
  • [46] Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis
    Hughes, Timothy P.
    Munhoz, Eduardo Ciliao
    Elhaddad, Alaa
    Chuan, Ong Tee
    Abdulkadyrov, Kudrat
    Shortt, Jake
    Quach, Hang
    Pavlovsky, Carolina
    Louw, Vernon J.
    Meillon, Luis
    Shih, Lee-Yung
    Turkina, Anna G.
    Hwang, Jonathan
    Nidamarthy, Prasanna Kumar
    Dalal, Darshan
    Lipton, Jeffrey H.
    BLOOD, 2014, 124 (21)
  • [47] Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
    Brummendorf, Tim H.
    Cortes, Jorge E.
    Milojkovic, Dragana
    Gambacorti-Passerini, Carlo
    Clark, Richard E.
    le Coutre, Philipp D.
    Garcia-Gutierrez, Valentin
    Chuah, Charles
    Kota, Vamsi
    Lipton, Jeffrey H.
    Rousselot, Philippe
    Mauro, Michael J.
    Hochhaus, Andreas
    Monroy, Rafael Hurtado
    Leip, Eric
    Purcell, Simon
    Yver, Anne
    Viqueira, Andrea
    Deininger, Michael W.
    BLOOD, 2020, 136
  • [48] Impact of Dose Reductions and Interruptions Due to Adverse Events (AEs)on Efficacy in Newly Diagnosed Chronic Myeloid Leukemia in ChronicPhase (CML-CP) Patients (pts) Receiving Either Dasatinib (D) or Imatinib(IM): Analysis of the DASISION Trial
    Jabbour, Elias
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    Guilhot, Francois
    Zhu, Chao
    Hong, Janet
    Cain, Zachary
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1191 - 1192
  • [49] Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study.
    Druker, B. J.
    Guilhot, F.
    O'Brien, S.
    Larson, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 338S - 338S
  • [50] Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib
    Li Weiming
    Zhang, Yanli
    Wu, Zhiwei
    Wen, Qin
    Leng, Qing
    Wu, Shuting
    Wang, Xiaodong
    Chen, Shiming
    Yuan, Guolin
    Qian, Sixuan
    Chen, Suning
    Jiang, Daozi
    Diao, Lianjun
    Xi, Zhenfang
    Wu, Hui
    Sun, Hui
    Yang, Lijie
    Wang, Hongjuan
    Zhang, Xuefang
    Xu, Yanli
    Zhao, Xielan
    Xu, Na
    Meng, Li
    Zhu, Zunmin
    Zhao, Youfang
    Su, Meifang
    Yang, Zhuangzhi
    Liu, Chuancai
    Han, Danlei
    Hu, Yu
    BLOOD, 2023, 142
12345